# Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

> **NCT06211036** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 563 (actual)

## Conditions studied

- Extensive-Stage Small-Cell Lung Cancer
- Small-Cell Lung Cancer

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06211036
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2027-07-05
- **Final completion:** 2028-09-30
- **Target enrollment:** 563 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06211036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06211036, "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06211036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*